Literature DB >> 22367101

Association of genetic polymorphisms in the paraoxonase 1 gene with the risk and prognosis of non-small cell lung cancer in Chinese Han population.

Hui Wang1, Lin Li, Li Ding, Zijin Zhang, Chun Pu.   

Abstract

OBJECTIVE: Oxidative stress and free radicals have been indicated to be associated with increased risk of various cancers. Paraoxonase 1 (PON1) gene, encoding PON1 protein, plays an important role as an endogenous free-radical scavenging molecule. The aim of the present study was to determine whether genetic polymorphisms of the PON1 gene are associated with the risk and prognosis of non-small cell lung cancer (NSCLC).
METHODS: A total of 356 patients with NSCLC and 184 healthy controls were enrolled in this study. Q192R and L55M polymorphisms of the PON1 gene were genotyped using polymerase chain reaction and restriction fragment length polymorphism method.
RESULTS: As for the Q192R polymorphism, the patients with NSCLC showed higher frequencies of QR and RR genotypes than the normal controls. Unconditional logistic regression analysis revealed that QR and RR genotypes were significantly associated with the presence of NSCLC compared with the QQ genotype. No significant differences were found in the genotypes of the L55M polymorphism between the patients with NSCLC and the healthy controls. The QR and RR genotypes were significantly associated with TNM stage and nodal metastasis. Survival analysis indicated that the patients with NSCLC with the QR and RR genotypes had poorer disease-free survival than those with the QQ genotype (P=0.011). Multivariable Cox regression analysis revealed that QR and RR genotypes were an independent factor for the prognosis of NSCLC (hazard ratio, 1.505; 95% confidence interval, 1.004-2.256; P=0.048).
CONCLUSION: The Q192R polymorphism of the PON1 gene may be associated with the risk and prognosis of NSCLC in a Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367101     DOI: 10.2310/JIM.0b013e318245d557

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  6 in total

1.  Interactions between paraoxonase 1 genetic polymorphisms and smoking and their effects on oxidative stress and lung cancer risk in a Korean population.

Authors:  Sang-Yong Eom; Dong-Hyuk Yim; Chul-Ho Lee; Kang-Hyeon Choe; Jin Young An; Kye Young Lee; Yong-Dae Kim; Heon Kim
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

2.  Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma.

Authors:  Hikmet Akkız; Sedef Kuran; Ersin Akgöllü; Oğuz Üsküdar; Aynur Bekar; Süleyman Bayram; Selçuk Yıldırım; Yakup Ülger; Berrin Yalınbaş Kaya; Mahmut Şansal; Ercan Çınar
Journal:  Meta Gene       Date:  2013-10-28

3.  Association between L55M polymorphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies.

Authors:  Lei Chen; Wei Lu; Lu Fang; Hu Xiong; Xun Wu; Meng Zhang; Song Wu; Dexin Yu
Journal:  Onco Targets Ther       Date:  2016-03-04       Impact factor: 4.147

4.  Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells.

Authors:  Mark Borris D Aldonza; Yeon Sung Son; Hye-Jin Sung; Jung Mo Ahn; Young-Jin Choi; Yong-In Kim; Sukki Cho; Je-Yoel Cho
Journal:  Oncotarget       Date:  2017-06-27

5.  Association between Paraoxonase 1 polymorphisms and risk of esophagogastric junction adenocarcinoma: a case-control study involving 2,740 subjects.

Authors:  Weifeng Tang; Jianchao Liu; Yafeng Wang; Yanchao Chen; Mingqiang Kang; Jun Yin; Chao Liu; Jing Lin; Yu Chen
Journal:  Oncotarget       Date:  2017-08-10

6.  Low paraoxonase 1 activity predicts mortality in surgical patients with sepsis.

Authors:  Suzana Bojic; Jelena Kotur-Stevuljevic; Nevena Kalezic; Zorana Jelic-Ivanovic; Aleksandra Stefanovic; Ivan Palibrk; Lidija Memon; Zdravko Kalaba; Marina Stojanovic; Sanja Simic-Ogrizovic
Journal:  Dis Markers       Date:  2014-02-09       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.